PMID- 19596914
OWN - NLM
STAT- MEDLINE
DCOM- 20090908
LR  - 20090714
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 29
IP  - 7
DP  - 2009 Jul
TI  - Immunobiological and experimental aspects of malignant astrocytoma.
PG  - 2461-5
AB  - Today several findings indicate that a multifactorial strategy is the best 
      strategy for treating cancer. Although radiotherapy, chemotherapy and surgery 
      have been differently applied to treat human gliomas, no substantial improvement 
      in life expectancy has been observed. Starting from 1992, the goal of our studies 
      was to obtain new biological data on malignant astrocytomas to better understand 
      the basic biology of the tumour and these are reviewed here. Immunotherapy may 
      represent an available method in addition to the traditional therapeutic 
      approaches. Starting from 1991, we set up a cellular model of lymphocytes 
      obtained from peripheral blood of healthy patients treated with interleukin-2 
      (IL-2) in order to study the role of IL-2 in regulating lymphocytes activation. 
      The lymphocytes responding to IL-2 treatment, named lymphokine-activated killer 
      (LAK) cells, have a killer non MHC restricted activity, and are able to kill 
      autologous and allogenic glioma cells. The interaction of LAK cells with various 
      normal and transformed targets indicates that LAK cells recognize surface 
      structures present both on normal and transformed cells. However, only the 
      interaction with transformed cells induces lytic events and LAK cells can act as 
      "surgical weapons" against tumour cells independently from their cell cycle. Much 
      recent effort has focused on identifying the immune escape mechanisms used by 
      glioma cells, in particular the modulation of the human leukocyte antigen (HLA) 
      and antigen processing machinery component expression. Finally, another 
      interesting field of research that will be presented is that of new tumour 
      biomarkers of proliferation and apoptosis, cytokine/chemokine release and 
      cytokine/chemokine receptors.
FAU - Nano, R
AU  - Nano R
AD  - Department of Animal Biology, University of Pavia, Piazza Botta 10, 27100 Pavia, 
      Italy. nano@unipv.it
FAU - Capelli, E
AU  - Capelli E
FAU - Facoetti, A
AU  - Facoetti A
FAU - Benericetti, E
AU  - Benericetti E
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Interleukin-2)
SB  - IM
MH  - Astrocytoma/*immunology/pathology/therapy
MH  - Brain Neoplasms/*immunology/pathology/therapy
MH  - Humans
MH  - Immunotherapy
MH  - Interleukin-2/blood/pharmacology/therapeutic use
MH  - Lymphocyte Activation/drug effects
RF  - 51
EDAT- 2009/07/15 09:00
MHDA- 2009/09/09 06:00
CRDT- 2009/07/15 09:00
PHST- 2009/07/15 09:00 [entrez]
PHST- 2009/07/15 09:00 [pubmed]
PHST- 2009/09/09 06:00 [medline]
AID - 29/7/2461 [pii]
PST - ppublish
SO  - Anticancer Res. 2009 Jul;29(7):2461-5.